Compare UPLD & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UPLD | PHIO |
|---|---|---|
| Founded | 2010 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 11.2M |
| IPO Year | 2014 | 2011 |
| Metric | UPLD | PHIO |
|---|---|---|
| Price | $4.88 | $1.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $3.75 | ★ $14.00 |
| AVG Volume (30 Days) | 29.5K | ★ 125.4K |
| Earning Date | 05-01-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.38 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $74,767,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.95 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 6.95 | N/A |
| 52 Week Low | $0.50 | $0.81 |
| 52 Week High | $6.65 | $4.19 |
| Indicator | UPLD | PHIO |
|---|---|---|
| Relative Strength Index (RSI) | 50.92 | 62.58 |
| Support Level | $4.01 | $0.99 |
| Resistance Level | $5.65 | $1.22 |
| Average True Range (ATR) | 0.67 | 0.06 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 30.16 | 75.56 |
Upland Software Inc is a software company. It provides cloud-based software applications in three categories: Knowledge Management that provides solutions designed to help organizations capture, organize, and distribute information to employees and customers. Content Lifecycle and Workflow Automation offers solutions that support document management, compliance, and process efficiency across various industries. Digital Marketing solutions that provides tools for audience engagement, campaign management, and content distribution across digital channels. Geographically, the company has operations in the U.S., United Kingdom and Canada, of which United States derives maximum revenue.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.